Jamie Christensen - Jan 4, 2022 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role: EVP, Chief Scientific Officer
Signature: /s/ Vickie Reed, Attorney-in-Fact
Stock symbol: MRTX
Transactions as of: Jan 4, 2022
Transactions value $: -$213,017
Form type: 4
Date filed: 1/6/2022, 03:51 PM
Previous filing: Dec 17, 2021
Next filing: Jan 18, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRTX	Common Stock	Sale	-$213K	-1.44K	-1.83%	$147.72	77.3K	Jan 4, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 3, 2020.
F2	The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $147.34 to $147.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Content

Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 3, 2020.

The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $147.34 to $147.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.